Fig. 7

RC48 combined with dabrafenib potently inhibit tumor growth in A2058 CDX model in vivo. The A2058 CDX model was established in BALB/c-nude mice, and mice bearing xenografts averaging approximately 100–150 mm³ were randomly allocated into four groups: vehicle (VEH), 5 mg/kg RC48, 20 mg/kg DAB, and their combination. A, B Tumor growth curve and inhibition rate of tumor growth (TGI) in the A2058 CDX model. C, D A2058 transplanted tumor weights and tumor images were evaluated at the end of the experiment. E Images of immunohistochemical staining for Ki67 in A2058 xenograft tumors, IHC images captured at 400× magnification. Scale bars , 20 µm. F Immunofluorescence TUNEL images of of A2058 xenograft tumors captured at 200× magnification. Scale bars, 50 µm. G The expression levels of PARP, Mcl-1, and p-Rb in A2058 xenograft tumors were examined using immunoblot analysis. H Pathological changes in these organs of the A2058 mouse CDX model were evaluated using H&E staining assays. Images captured at 400× magnification. Scale bars , 20 µm. Data represent the mean ± SEM of at least three independent experiments, and statistical significance was assessed using an unpaired t-test (*p < 0.05; **p < 0.01; ***p < 0.001)